Skip to content

Pilot scale production of functional ingredients for produce glucose-lowering supplements and evaluate the effectiveness of products

Pilot scale production of functional ingredients for produce glucose-lowering supplements and evaluate the effectiveness of products

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250512003
Enrollment
48
Registered
2025-05-12
Start date
2024-06-03
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pre-diabetes anthocyanins, concurrent training, Type 2 diabetes, obesity, inflammation

Interventions

The control group consume 1 capsules of maltodextrin per day, which were virtually identical in size, shape, and color for 8 weeks.,The anthocyanins and polyphenols supplementation group consume 1 cap
Placebo control group (PLA group),EAT ME extract which contains anthocyanins and polyphenols supplementation (EAT-ME group),Combined exercise training group (CBT group),EAT ME extract which contains a

Sponsors

Program Management Unit (PMU)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Male and female ages between 20 and 50 years 2. A body mass index of 23 kg per square meter or more. 3. Blood glucose level after not eating for at least 8 hours in the range of 100 to 125 ml/dl 4. A 21 percent or higher body fat percentage 5. Those who exercise less than 20 minutes per day and less than two days per week for more than six months. 6. No disease or injury related to the joints, bones, or muscles will hinder exercise. 7. Able to understand and communicate 8. A willingness to participate in volunteer research studies

Exclusion criteria

Exclusion criteria: 1. Heavy smoking more than three times a week (more than three servings at a time). 2. Drink alcohol heavily, more than three times a week, consuming more than three servings at a time. 3. A chronic illness with kidney and liver disease. 4. Respiratory diseases 5. Thyroid disease or abnormalities in hormone levels related to the metabolic system. 6. Uncontrolled cardiovascular disease. 7. Pregnant or breastfeeding 8. Being a person with a disability

Design outcomes

Primary

MeasureTime frame
Fasting blood glucose, HbA1c, Insulin, HOMA-IR, IL-6, TNF-alpha, hs-CRP before and after 8 weeks at the end of the intervention Blood chemistry analysis,Body composition before and after 8 weeks at the end of the intervention DEXA,Physical fitness before and after 8 weeks at the end of the intervention Physical fitness test

Secondary

MeasureTime frame
Heart rate variabilty before and after 8 weeks at the end of the intervention eMotion Faros device,quality of life before and after 8 weeks at the end of the intervention SF-36,baPWV before and after 8 weeks at the end of the intervention pulse wave velocity,substrate utilization before and after 8 weeks at the end of the intervention gas analysis

Countries

Thailand

Contacts

Public ContactJatuporn Phoemsapthawee

Faculty of Sports and Health Science, Kasetsart University

jatuporn.w@ku.th034355258

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026